Leading Scientists Demonstrate How Seer’s Proteograph Product Suite Advances Cardiovascular and Neurodegenerative Research at US HUPO 2026

Seer (NASDAQ: SEER) will participate in US HUPO 2026 in St.

Rhea-AI Summary

Seer (NASDAQ: SEER) will participate in US HUPO 2026 in St. Louis, Feb 21–25, showcasing the Proteograph Product Suite across posters, oral sessions, and a breakfast symposium on Feb 24. Presentations span cardiovascular disease, neurodegeneration, aging biology, oncology, and population-scale proteomics, highlighting deep, scalable nanoparticle-enabled proteomics.

Speakers include Sasha A. Singh, Nathan Basisty, Bruce Wilcox, and Mozhgan Boroumand; Singh reports quantifying >5,000 proteins from 75 µL plasma per sample.

Argus Feb 19 session

+2.48% close to close Open Argus

Details

News Market Reaction – SEER

On Feb 19, the day this news came out, SEER closed 2.48% above the previous close.

Data tracked by StockTitan Argus for the Feb 19 session.

Key Figures

Conference dates: February 21–25, 2026 Presentation count: More than a dozen Plasma volume per sample: 75 µL +5 more

Conference dates

February 21–25, 2026

US HUPO 2026 annual conference schedule

Presentation count

More than a dozen

Scientific presentations featuring Seer’s technology at US HUPO 2026

Plasma volume per sample

75 µL

Mouse atherosclerosis model plasma analyzed with Proteograph workflow

Proteins quantified

More than 5,000 proteins

Reproducible quantification in murine atherosclerosis plasma study

Proteome depth increase

More than tenfold

Increase in proteome depth versus conventional approaches

Breakfast symposium time

7:15–8:15 a.m. CT

Nanoparticle-enabled plasma proteomics symposium on February 24

Plenary talk time

8:30–9:05 a.m. CT

Nathan Basisty plenary session on translational geroscience

Pre-news share price

$2.02

Last close before US HUPO 2026 announcement

Historical Context

5 past events · Latest: Feb 05

5 events

1. Feb 05

   Earnings date notice

   24h Move

   +2.3%

   Announced timing for Q4 and full-year 2025 earnings release and call.

2. Dec 01

   Platform validation study

   24h Move

   -1.0%

   Nature Genetics study validated Proteograph for population-scale proteomics and biomarker work.

3. Nov 07

   HUPO 2025 data

   24h Move

   -3.2%

   Announced extensive HUPO 2025 presentations showcasing Proteograph in multiple disease areas.

4. Nov 06

   Q3 2025 earnings

   24h Move

   -0.5%

   Reported higher revenue, improved loss metrics, and reiterated full-year 2025 guidance.

5. Oct 29

   Investor conferences

   24h Move

   -3.1%

   Outlined participation in two November 2025 healthcare investor conferences.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

proteomics, mass spectrometry, nanoparticle-enabled proteomics, plasma proteomics, +4 more

8 terms

proteomics medical

"the pioneer and trusted partner for deep, unbiased proteomic insights"

Proteomics is the large-scale study of all the proteins produced by a cell, tissue or organism, like taking a full inventory and watching how the workforce and machines inside a factory behave. For investors, proteomics matters because it helps identify drug targets, disease indicators and responses to treatments—information that can speed development, reduce risk, guide partnerships and reveal new commercial opportunities in biotech and diagnostics.

mass spectrometry technical

"more reproducible mass spectrometry measurement of the human proteome"

Mass spectrometry is a laboratory technique that identifies and measures chemicals by giving molecules an electrical charge and sorting them by how fast they move, like weighing and separating coins to see which kinds are present. For investors, its results are evidence used in drug development, quality control, food and environmental testing, and diagnostics, so clear mass-spec data can affect regulatory approval, product reliability, costs and market confidence.

nanoparticle-enabled proteomics technical

"growing adoption of nanoparticle-enabled proteomics across translational and population-scale research"

Tiny engineered particles used to grab, concentrate and study proteins from biological samples, making it easier to find and measure many different proteins at once. Think of them as tiny fishing hooks that pull specific molecules out of a complex soup so researchers can identify disease signals, drug effects or biomarkers faster and with less sample. For investors, the approach can speed development of diagnostics and therapies, lower lab costs, and create commercially valuable tools or data that may drive revenue or partnerships.

plasma proteomics medical

"Addressing the Plasma Proteomics Needs of Large-Scale Clinical Cohorts"

Plasma proteomics is the study and measurement of the full set of proteins circulating in blood plasma, using tools that identify and quantify hundreds to thousands of proteins at once. For investors, it matters because changes in these protein patterns can become biomarkers used to diagnose disease, track treatment effects, or unlock new drug targets—think of it as reading the body’s protein weather to predict health and commercial value.

multi-omics technical

"Translating Multi-Omics Discoveries into a Protein-Based LDT for Lung Cancer"

Multi-omics is a comprehensive approach that combines different types of biological data—such as genetic information, proteins, and other molecules—to gain a detailed understanding of how living systems function. For investors, this approach can reveal insights into health, disease, or biological processes that may influence the development of new treatments or technologies, potentially impacting market opportunities and innovation in healthcare.

biomarkers medical

"aging biology into biomarkers and therapeutic strategies"

Biomarkers are measurable indicators found in the body, such as substances in blood or tissues, that reveal information about health or disease. For investors, they can signal how well a medical treatment is working or whether a disease is developing, helping to assess the potential success or risks of healthcare companies or innovations. Think of biomarkers as biological signals that provide clues about a person’s health status.

nanoparticle-based enrichment technical

"Using a Novel Nanoparticle-Based Enrichment Workflow"

Nanoparticle-based enrichment uses tiny engineered particles to selectively grab and concentrate specific molecules—such as proteins, DNA, or virus particles—from a complex sample, like pulling out needles from a haystack with a magnet. For investors, it matters because this step can make diagnostic tests and lab assays much more sensitive, faster or cheaper, increasing the commercial value of a technology, affecting regulatory approval chances, and shaping competitive advantage and adoption in healthcare markets.

dia proteomics technical

"Accurate Quantitative DIA Proteomics for Thousands of Samples"

DIA proteomics is a laboratory method that measures and catalogues many proteins in a biological sample at once using a mass spectrometer, capturing signals from all fragments rather than selecting a few targets. For investors, it matters because it enables more consistent, repeatable detection of potential disease markers and drug effects—like taking a high-resolution group photo instead of a series of selective snapshots—reducing technical blind spots and improving the reliability of biomarker and drug-development data.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Nathan Basisty, Sasha Singh, Bruce Wilcox, and Mozhgan Boroumand among scientific leaders presenting unique proteomics-enabled biological insights

REDWOOD CITY, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced its participation in the 2026 U.S. Human Proteome Organization (US HUPO) Annual Conference, taking place February 21-25 in St. Louis, Missouri. At the meeting, researchers will demonstrate how Seer’s Proteograph^® Product Suite is enabling them to tackle complex questions in major disease areas, while supporting the scaling requirements needed for clinical and population health applications.

US HUPO has emerged as an important venue for evaluating how new proteomic technologies perform when applied to real-world research challenges. At US HUPO 2026, Seer will be featured across more than a dozen scientific presentations spanning posters, oral sessions, and plenary talks, reflecting the growing adoption of nanoparticle-enabled proteomics across translational and population-scale research. This year’s presentations span cardiovascular disease, neurodegeneration, aging biology, oncology, and computational advances, underscoring how deep, scalable proteomics is helping bridge laboratory discovery with human health outcomes.

Attendees can connect with the Seer team at Booth #18, explore poster presentations featuring biological insights enabled by the Proteograph Product Suite, and attend a breakfast symposium highlighting breakthrough findings in cardiovascular disease research.

"The work being presented at US HUPO reflects a broader shift in proteomics toward deeper, more scalable, and more reproducible mass spectrometry measurement of the human proteome that is enabled by the Proteograph Product Suite," said David Horn, President and Chief Financial Officer at Seer. "As researchers apply the Proteograph solution to their complex disease models and large-scale cohorts, we are seeing strong validation of the Proteograph’s scientific impact and its strategic importance to advancing translational research at scale.”

Seer Breakfast Symposium

Nanoparticle-Enabled Plasma Proteomics of a Mouse Atherosclerosis Model

Date: Tuesday, February 24 | Time: 7:15–8:15 a.m. CT | Location: Room Grand GH

Speaker: Sasha A. Singh, PhD, Assistant Professor of Medicine, Harvard Medical School

In Tuesday’s symposium, Dr. Singh will present how her laboratory applied the Proteograph Product Suite to deeply profile plasma in a murine model of atherosclerosis, addressing long-standing challenges in detecting low-abundance proteins from small-volume samples. Using just 75 µL of plasma per sample, the workflow enabled reproducible quantification of more than 5,000 proteins, representing more than a tenfold increase in proteome depth compared with conventional approaches.

US HUPO Plenary Session Highlight

Nathan Basisty, PhD, NIH Distinguished Scholar and Tenure Track Investigator at the National Institute on Aging, will present during the Robert J. Cotter New Investigator Award Plenary Session on Tuesday, February 24 (8:30–9:05 a.m. CT). His talk, Paving the Road to Translational Geroscience with Proteomics, will explore how advances in proteomic technologies are accelerating the translation of aging biology into biomarkers and therapeutic strategies.

Additional Scientific Presentations Featuring Seer Technology

Seer-enabled research will be featured across a broad set of oral presentations, plenary sessions, and posters throughout US HUPO 2026, highlighting the application of deep, scalable proteomics to cardiovascular disease, neurodegeneration, oncology, aging biology, and population-scale workflows.

Invited Speaker Presentations

• Pathways and Pitfalls in Translating Multi-Omics Discoveries into a Protein-Based LDT for Lung Cancer
  Bruce Wilcox, PrognomiQ
  February 24 | 9:15 AM | Room Grand DE

• Linking Tissue-Specific Senescence Burden to Circulating Protein Signatures Using a Novel Nanoparticle-Based Enrichment Workflow
  Mozhgan Boroumand, National Institute on Aging, NIH
  February 24 | 9:57 AM | Room Grand DE

Oral and Poster Presentations

• Unbiased Deep Proteomic Profiling of Conditioned Media and Cerebrospinal Fluid Using a Nanoparticle-Based Workflow
  Presenter: A. Gajadhar | Poster Session 1 | February 23, 4:30–6:30 PM CT
• Systematic Proteomic Architecture of Neurodegeneration Reveals Translation and Vesicular Dysregulation as Upstream Drivers of Neuronal Decline
  Presenter: A. Siddiqui | Poster Session 1 | February 23, 4:30–6:30 PM CT
• Evaluating Nanoparticle-Based Enrichment of Cell Lysates for Automated, Global Proteome Analysis
  Presenter: E. Stancliffe | Poster Session 1 | February 23, 4:30–6:30 PM CT

• Addressing the Plasma Proteomics Needs of Large-Scale Clinical Cohorts
  Presenter: C. Kempf | Poster Session 1 | February 23, 4:30–6:30 PM CT
• Accelerating Biomarker Discovery with High-Depth, Whole Patient Multimodal Proteomics and Transcriptomics
  Presenter: D. Gutierrez | Poster Session 1 | February 23, 4:30–6:30 PM CT

• From Peaks to Power: Context-Driven Determinants of Accuracy in Biologically Resolved Proteomics
  Presenter: L. Cantrell | Poster Session 2 | February 24, 4:30–6:30 PM CT
• A Cloud-Native Pipeline Enabling Fast, Sensitive, and Accurate Quantitative DIA Proteomics for Thousands of Samples
  Presenter: S. Just | Poster Session 2 | February 24, 4:30–6:30 PM CT
• Comprehensive Plasma Proteomic Analysis of Systemic Changes Following Chemotherapy in Breast Cancer Patients
  Presenter: L. Herring | Poster Session 2 | February 24, 4:30–6:30 PM CT
• Aging-Associated Plasma Proteome Changes in Healthy Non-Human Primates
  Presenter: D. Key Planas | Poster Session 2 | February 24, 4:30–6:30 PM CT
• An Optimized Workflow for Plasma Proteomics
  Presenter: D. Key Planas | Poster Session 2 | February 24, 4:30–6:30 PM CT
  

Together, these presentations reflect the expanding role of Proteograph-enabled workflows in advancing biological insight across disease areas while supporting reproducible, high-throughput proteomics at scale.

About Seer, Inc.

Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics, delivering insights with a scale, speed, precision and reproducibility previously unattainable. Seer's Proteograph^® Product Suite integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables and advanced analytical software to overcome the limitations of traditional proteomic methods. Seer's products are for research use only and are not intended for diagnostic procedures. For more information, visit www.seer.bio.

For more information, please visit Booth #18 at US HUPO 2026 or contact us at pr@seer.bio.

Media Contact:
Patrick Schmidt
pr@seer.bio

Investor Contact:
Kelly Gura
investor@seer.bio

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What will Seer present at US HUPO 2026 (SEER) in St. Louis on Feb 24, 2026?

Seer will feature talks, posters, and a Feb 24 breakfast symposium highlighting Proteograph-enabled studies in cardiovascular and aging research. According to Seer, speakers include Sasha A. Singh and Nathan Basisty, and sessions demonstrate deep, scalable nanoparticle-enabled plasma proteomics across disease areas.

How many proteins did Sasha A. Singh quantify using Proteograph at US HUPO 2026 (SEER)?

Dr. Sasha A. Singh reported reproducible quantification of more than 5,000 proteins from 75 µL plasma per sample. According to Seer, that represents over a tenfold increase in proteome depth versus conventional approaches for small-volume samples.

Which disease areas will Seer (SEER) showcase at the US HUPO 2026 conference?

Seer will highlight applications in cardiovascular disease, neurodegeneration, aging biology, oncology, and population-scale workflows. According to Seer, presentations across posters, oral sessions, and plenaries demonstrate Proteograph use in translational and population-scale proteomics research.

When and where is the Seer breakfast symposium at US HUPO 2026 for SEER investors or attendees?

The Seer breakfast symposium is scheduled for Tuesday, Feb 24, 7:15–8:15 a.m. CT in Room Grand GH, focusing on nanoparticle-enabled plasma proteomics of a mouse atherosclerosis model. According to Seer, Sasha A. Singh is the featured speaker.

Which Seer (SEER) researchers are presenting plenary or invited talks at US HUPO 2026?

Nathan Basisty will present in the Robert J. Cotter New Investigator Award Plenary and invited speakers include Bruce Wilcox and Mozhgan Boroumand. According to Seer, these presentations address translational geroscience, LDT translation, and senescence-linked proteomics.

How is the Proteograph Product Suite positioned for large-scale clinical and population studies, according to Seer (SEER)?

Seer positions Proteograph as enabling deep, reproducible, and scalable proteomics suitable for clinical and population cohorts. According to Seer, the technology supports high-throughput workflows and nanoparticle-based enrichment to address low-abundance protein detection at scale.